GlassScriptPhysician profile
Alejandro Inclan
NPI 1023003456
$1,333.86
in general payments reported to CMS, 2019-2025
25 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2021: $86.31 · 2022: $428 · 2023: $222 · 2024: $242 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $529 · Education: $43.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.85 |
| Education | $43.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $244.42 | 2019-2022 | |
| Astellas Pharma US INC | $202.96 | 2021-2025 | Xtandi, Padcev |
| Celgene Corporation | $138.18 | 2022-2025 | Pomalyst, Reblozyl |
| Abbvie INC. | $98.41 | 2022-2025 | |
| Pfizer INC. | $80.01 | 2019-2024 | |
| Mirati Therapeutics, INC. | $77.64 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $53.22 | 2022-2023 | Yescarta |
| Adaptive Biotechnologies Corporation | $41.24 | 2023-2025 | Clonoseq |
| Sun Pharmaceutical Industries INC. | $39.86 | 2023 | Odomzo, Yonsa |
| Genentech USA, INC. | $30.94 | 2022 | |
| Eisai INC. | $30.19 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.92 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2022 | |
| Seagen INC. | $26.22 | 2023 | Adcetris |
| Csl Behring | $26.16 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $24.15 | 2022 | |
| Array Biopharma INC | $24.00 | 2022 | |
| Epizyme, INC. | $23.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.21 | 2024 | Imfinzi |
| Tempus Ai, INC | $20.90 | 2024 | Xt Cdx |
| Stemline Therapeutics INC. | $18.72 | 2025 | Orserdu |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Springworks Therapeutics, INC. | $13.42 | 2024 | Ogsiveo |
| Emd Serono, INC. | $12.57 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Inclan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.